Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …

The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

Substantial progress has been made in our understanding of the pathogenetic basis of
myeloproliferative neoplasms. The discovery of mutations in JAK2 over a decade ago …

Clonal hematopoiesis (CH), the expansion of hematopoietic stem cells and their progeny
driven by somatic mutations in leukemia-associated genes, is a common phenomenon that …

Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a
heterogeneous group of clonal hematopoietic stem cell disorders characterized by an …

Abstract Calreticulin (CALR)+ 1 frameshift mutations in exon 9 are prevalent in
myeloproliferative neoplasms. Mutant CALRs possess a new C-terminal sequence rich in …

A well-functioning hematopoietic system requires a certain robustness and flexibility to
maintain appropriate quantities of functional mature blood cells, such as red blood cells and …

Mutant calreticulin (CALR) proteins resulting from a− 1/+ 2 frameshifting mutation of the
CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of …

Calreticulin (CALR) mutations present the main oncogenic drivers in JAK2 wildtype (WT)
myeloproliferative neoplasms (MPN), including essential thrombocythemia and …

Despite distinct clinical entities, the myeloproliferative neoplasms (MPN) share
morphological similarities, propensity to thrombotic events and leukemic evolution, and a …